

Dendritic/antigen presenting cell mediated provision of T-cell receptor gamma delta (TCR $\gamma\delta$) expressing cells contributes to improving antileukemic reactions ex vivo

Elias Rackl^a, Anne Hartz^a, Hazal Aslan Rejeski^a, Lin Li^a, Lara Kristina Klauer^a, Selda Ugur^a, Elena Pepeldjiyska^a, Carina Amend^a, Melanie Weinmann^a, Fatemeh Doraneh-Gard^a, Julian Stein^a, Nina Reiter^a, Corinna L. Seidel^b, Caroline Plett^a, Daniel Christoph Amberger^a, Peter Bojko^c, Doris Kraemer^d, Jörg Schmohl^e, Andreas Rank^{f,g}, Christoph Schmid^{f,g}, Helga Maria Schmetzer^{a,g,*}

^a Department of Medicine III, University Hospital of Munich, Munich 81377, Germany

^b Department of Orthodontics and Dentofacial Orthopedics, University Hospital, LMU Munich, Munich 80336, Germany

^c Department of Hematology and Oncology, Rotkreuzklinikum Munich, Munich 80634, Germany

^d Department of Hematology and Oncology, St.-Josefs-Hospital, Hagen 58097, Germany

^e Department of Hematology and Oncology, Diakoniekrankenhaus Stuttgart, Stuttgart 70176, Germany

^f Department of Hematology and Oncology, University Hospital of Augsburg, Augsburg 86156, Germany

^g Bavarian Cancer Research Center (BZKF) Comprehensive Cancer Center, Germany

ARTICLE INFO

Keywords:

T cell receptors
Dendritic cells
Antigen presenting cells
Cell therapy
Immunomodulation
Leukemia

ABSTRACT

T-cell receptor gamma delta (TCR $\gamma\delta$) expressing T-cells are known to mediate an MHC-independent immune response and could therefore qualify for immune therapies. We examined the influence of dendritic cells(DC)/antigen presenting cell (APC) generated from blast-containing whole blood (WB) samples from AML and MDS patients on the provision of (leukemia-specific) TCR $\gamma\delta$ expressing T-cells after mixed lymphocyte culture (MLC). Kit-M (granulocyte-macrophage colony-stimulating factor (GM-CSF) + prostaglandin E1 (PGE1)) or Kit-I (GM-CSF + Picibanil) were used to generate leukemia derived APC/DC (DC_{leu}) from WB, which were subsequently used to stimulate T-cell enriched MLC. Immune cell composition and functionality were analysed using degranulation- (DEG), intracellular cytokine- (INTCYT) and cytotoxicity fluorolysis- (CTX) assays. Flow cytometry was used for cell quantification. We found increased frequencies of APCs/DCs and their subtypes after Kit-treatment of healthy and patients' WB compared to control, as well as an increased stimulation and activation of several types of immune reactive cells after MLC. Higher frequencies of TCR $\gamma\delta$ expressing leukemia-specific degranulation and intracellularly cytokine producing T-cells were found. The effect of Kit-M-treatment on frequencies of TCR $\gamma\delta$ expressing cells and their degranulation could be correlated with the Kit-M-mediated blast lysis compared to control. We also found higher frequencies of TCR $\gamma\delta$ expressing T-cells in AML patients' samples with an achieved remission (compared to blast persistence) after induction chemotherapy. This might point to APC/DC-mediated effects resulting in the provision of leukemia-specific TCR $\gamma\delta$ expressing T-cells: Moreover a quantification of TCR $\gamma\delta$ expressing T-cells might contribute to predict prognosis of AML/MDS patients.

* Corresponding author at: Department of Medicine III, University Hospital of Munich, Munich 81377, Germany.

E-mail addresses: elias.rackl@hotmail.de (E. Rackl), as.hartz@t-online.de (A. Hartz), hazlaslan@gmail.com (H. Aslan Rejeski), lilin199209106666@gmail.com (L. Li), lara.klauer@kabelmail.de (L.K. Klauer), seldaugur94@hotmail.de (S. Ugur), elena.pepeldjiyska@gmail.com (E. Pepeldjiyska), carina.gunsilius@web.de (C. Amend), melli.weinmann@hotmail.de (M. Weinmann), nikoo.792000@yahoo.com (F. Doraneh-Gard), julian.stein@med.uni-muenchen.de (J. Stein), nina.d.reiter@web.de (N. Reiter), corinna.seidel@uk-erlangen.de (C.L. Seidel), caroline.plett@googlemail.com (C. Plett), daniel.amberger@gmx.at (D.C. Amberger), peter.bojko@swmbrk.de (P. Bojko), kraemer@kkh-hagen.de (D. Kraemer), joerg.schmohl@diak-stuttgart.de (J. Schmohl), andreas.rank@uk-augsburg.de (A. Rank), christoph.schmid@uk-augsburg.de (C. Schmid), helga.schmetzer@med.uni-muenchen.de (H.M. Schmetzer).

<https://doi.org/10.1016/j.molimm.2024.09.007>

Received 20 June 2024; Received in revised form 28 August 2024; Accepted 13 September 2024

Available online 20 September 2024

0161-5890/© 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

1.1. Current therapy strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)

Risk adapted standard strategies for AML/ high-grade MDS result in impressive remission rates of 66–90% after 1–2 therapy cycles in AML. However, within two years, ensue in relapses in up to 80% of cases (Garcia-Manero et al., 2020, Estey, 2020). For patients with less tolerance for the induction therapy low-dose cytarabine or hypomethylating agents + venetoclax are potential therapy strategies (Dinardo et al., 2020). However, treatment options are limited and prognosis unfavorable for patients with relapsed or refractory disease (Thol et al., 2024). There is a high demand for development and adaption of immuno- and chemotherapies to stabilize remissions (or progredient disease) in AML/MDS cases, e.g. therapies utilizing specific chimeric antigen receptor (CAR)-T-cells, tyrosine kinase inhibitors, bispecific antibodies (BiTEs) and antigen-presenting cells (APCs) such as dendritic cells (DCs) (Estey, 2020, Garcia-Manero et al., 2020).

1.2. The potential of DCs as APCs for immune therapies

Hematopoietic stem cells and monocytes are able to differentiate into DCs as the result of complex maturation and activation processes. The differentiation processes involve upregulation of various receptors, such as cell adhesion receptors or chemokine receptors (e.g. CCR7), MHC-antigens and a variety of costimulatory factors (Behrends et al., 2016, Amberger et al., 2019, Amberger and Schmetzer, 2020).

DCs can be generated ex vivo: as monocyte-derived DC loaded with

tumor antigens (Amberger and Schmetzer, 2020) or leukemia-derived DC (DC_{leu}) generated from myeloid blasts (presenting the patients' individual tumor antigens), which can be generated in cultures and adoptively transferred to patients. Combining designated response modifiers into Kits can generate APCs/DC/DC_{leu} from cells in whole blood (WB) (e.g. Kit-M: GM-CSF (granulocyte macrophage colony stimulating factor) + PGE1 (prostaglandin E1) or Kit-I: GM-CSF+Pici-banil) (Amberger and Schmetzer, 2020, Ansprengrer et al., 2020, Kremser et al., 2010). This APC/DC generation was shown to be achieved without an induction of blast-proliferation (blasts co-expressing CD71 (Bla_{prol}-CD71; transferrin receptor) or IPO38 (Bla_{prol}-IPO38; intra-cellular marker for proliferation); see Table 1) (Amberger et al., 2019, Grabrucker et al., 2010, Schmetzer et al., 2007, Plett et al., 2022). Moreover we could already show, that Kit-treated patients' WB lead to improved leukemia specific/antileukemic activity after MLC (Klauer et al., 2022; Rackl et al., 2022; Schutti et al., 2024).

Mode of action of these response modifier mediated APC/DC generation is given in Supplementary Figure 1: two combined response modifiers (GM-CSF+PGE1 (Kit M) or GM-CSF+Pici-banil) are crucial to convert leukemic cells into DC_{leu}. The myeloid differentiation factor fosters the creation of DC progenitors (and in vivo hematological recovery) (Amberger et al., 2019, Schmetzer et al., 2022, Yu et al., 2022): The second factor (either PGE1 or Pici-banil) mediate a danger signal as well as maturation of DCs/DC_{leu}s (Schwepcke et al., 2022). Both signals trigger the reprogramming of the cancer cell to an APC/DC_{leu} and boost healthy DCs (Amberger et al., 2019, Klauer et al., 2024). Supplementary Figure 1.A). Finally those APC/DC or DC_{leu} mediate an (antigen specific) activation of the innate and the adaptive immune system, are responsible for effector functions (kill of infected cells or of leukemic cells in

Table 1
Cell subpopulations.

group	subgroup	acronym	markers	abbrev. [referred to cell fraction]	reference
blasts	blasts	Bla	CD15, CD34, CD65, CD117,	Bla/cells	(Campana and Behm, 2000)
dendritic cells	proliferating blasts	Bla _{prol} -CD71	CD71 ⁺ Bla ⁺ DC ⁺	Bla _{prol} -CD71/Bla	(Klauer et al., 2024)
	proliferating blasts	Bla _{prol} -IPO38	IPO38 ⁺ Bla ⁺ DC ⁺	Bla _{prol} -IPO38/Bla	(Klauer et al., 2024)
	antigen presenting cells/ dendritic cells	APC/DC	CD80, CD206, CD209, CD83	DC/cells	(Schmetzer et al., 2007)
	mature DC	DC _{mat}	DC ⁺ CCR7 ⁺	DC _{mat} /cells DC _{mat} /DC	(Schutti et al., 2024)
	leukemia derived DC	DC _{leu}	Bla ⁺ DC ⁺	DC _{leu} /cells DC _{leu} /DC DC _{leu} /Bla	(Schmetzer et al., 2007)
T-cells	mature leukemia derived DC	D _{leu} -mat	Bla ⁺ DC ⁺ CCR7 ⁺	DC _{leu} -mat/cells DC _{leu} -mat/DC _{leu} DC _{leu} -mat/DC _{mat}	(Klauer et al., 2024)
	T-cells	T	CD3 ⁺	CD3 ⁺ /cells	(Schick et al., 2013)
	Transferrin-R positive late proliferating T-cells	T _{prol-late}	CD3 ⁺ CD71 ⁺	T _{prol-late} /CD3 ⁺	(Schick et al., 2013)
	Type II C- type lectin positive early proliferating T-cells	T _{prol-early}	CD3 ⁺ CD69 ⁺	T _{prol-early} /CD3 ⁺	(Schick et al., 2013)
	CD4 positive T-cells	T _{CD4+}	CD4 ⁺ CD3 ⁺	T _{CD4+} /CD3 ⁺	(Schick et al., 2013)
	CD4 negative T-cells	T _{CD4-}	CD4 ⁺ CD3 ⁺	T _{CD4-} /CD3 ⁺	(Schick et al., 2013)
	non-naive T-cells	T _{non-naive}	CD3 ⁺ CD45RO ⁺	T _{non-naive} /CD3 ⁺	(Vogt et al., 2014)
	naive T-cells	T _{naive}	CD3 ⁺ CD45RO ⁻	T _{naive} /CD3 ⁺	(Vogt et al., 2014)
	central memory T-cells	T _{cm}	CD3 ⁺ CD45RO ⁺ CCR7 ⁺	T _{cm} /CD3 ⁺	(Vogt et al., 2014)
	CD4 positive non-naive T-cells	T _{non-naive} CD4 ⁺	CD3 ⁺ CD4 ⁺ CD45RO ⁺	T _{non-naive} CD4 ⁺ /T _{CD4+}	(Amberger et al., 2019)
TCRγδ others	CD4 negative non-naive T-cells	T _{non-naive} CD4 ⁻	CD3 ⁺ CD4 ⁻ CD45RO ⁺	T _{non-naive} CD4 ⁻ /T _{CD4-}	(Amberger et al., 2019)
	TCRγδ positive T-cells	T _{TCRγδ+}	TCRγδ ⁺ CD3 ⁺	T _{TCRγδ+} /CD3 ⁺	(Bensussan et al., 1989)
	cytokine induced killer cells	CIK	CD3 ⁺ CD56 ⁺	CIK/cells	(Amberger et al., 2019)
	natural killer cells	NK	CD3 ⁺ CD56 ⁺	NK/cells	(Amberger et al., 2019)
	monocytes	Mon	CD14 ⁺	Mon/cells	(Amberger et al., 2019)
DEG	proliferating monocytes	Mon _{prol} -CD71	CD71 ⁺ CD14 ⁺ DC ⁺	Mon _{prol} -CD71/Mon	(Amberger et al., 2019)
	B-cells	B	CD19 ⁺	Bcell/cells	
	CD107a positive TCRγδ positive T-cells	T _{TCRγδ+107a+}	CD107a ⁺ TCRγδ ⁺ CD3 ⁺	T _{TCRγδ+107a+} /T _{TCRγδ+}	
INTCYT	TNF alpha positive TCRγδ positive T-cells	T _{TCRγδ+TNFα+}	TNFα ⁺ TCRγδ ⁺ CD3 ⁺	T _{TCRγδ+TNFα+} /T _{TCRγδ+}	(Rodríguez-Caballero et al., 2004, Schutti et al., 2024)

abbrev. subpopulation; markers (measured by FACS) marker combinations;

case of leukemia (Supplementary Figure 1.B) (Dorane-Gard et al., 2024, Unterfrauner et al., 2023, Klauer et al., 2024).

1.3. Innate and adaptive immune system

The immune system utilizes humoral and cellular defense mechanisms against pathogens and tumor cells (Parkin and Cohen, 2001, Dunn et al., 2002). Macrophages ($CD15^+$), monocytes ($CD14^+$), APCs/DCs ($CD80^+$, $CD206^+$, etc. (Azad et al., 2014, Paurević et al., 2024)) and cytokine induced killer cells (CIK, $CD56^+CD3^+$) and natural killer cells (NK, $CD56^+CD3^-$): the innate immune system responsible for a first-line response against pathogens and tumors (Beutler, 2004, Grabrucker et al., 2010, Schmeel et al., 2015, Franks et al., 2020). The adaptive immunity is responsible for long-term immunity: B-cells ($CD19^+$) as well as T-cells ($CD3^+$) and their subpopulations (see Table 2): naive T-cells ($CD3^+CD45RO^-$: T_{naive}), non-naive T-cells ($CD3^+CD45RO^+$: $T_{non-naive}$; $CD3^+CD4^+CD45RO^+$: $T_{non-naiveCD4+}$ and $CD3^+CD4^+CD45RO^+$: $T_{non-naiveCD4-}$) after stimulation, $CD4^+CD3^+$ (T_{CD4+}) and $CD4^+CD3^-$ (T_{CD4-}) as mediators of immune responses and central memory cells ($CD3^+CD45RO^+CCR7^+$: T_{cm}) recognizing reoccurring antigens (Amberger et al., 2019, Boeck et al., 2017, Bonilla and Oettgen, 2010).

1.4. T-cell receptor gamma delta (TCR $\gamma\delta$)

T-cell receptors (TCR) are responsible for the antigen-induced proliferation and activation of T-cells (Alcover et al., 2018). While the alpha beta heterodimer of TCR (TCR $\alpha\beta$) is able to recognize antigens almost exclusively in association with major histocompatibility complex (MHC) molecules, TCR $\gamma\delta$ has the ability of MHC-independently recognizing antigens (Alcover et al., 2018, Hayday, 2000, Morath and Schamel, 2020). TCR $\gamma\delta$ expressing T-cells can be activated by various mechanisms, including indirectly by APCs/DCs via cytokines (Hannani et al., 2012, Devilder et al., 2006) and by leukemic cells (Duval et al., 1995). TCR $\gamma\delta$ expressing T-cells themselves are also able to modulate DCs and $CD8^+$ T-cell-activity via cytokines (Nakamizo et al., 2015). TCR $\gamma\delta$ expressing T-cells have been accredited with a high potential for immune therapy (Saura-Esteller et al., 2022, Vantourout and Hayday, 2013, Mensurado et al., 2023) and antileukemic activity (Minculescu et al., 2019, Bensussan et al., 1989, Costa et al., 2023). Enhanced cytolytic activity of $\gamma\delta$ TCR-T cells against tumor cells has also recently been observed (Davies et al., 2024). $CD19$ -specific $\gamma\delta$ TCR-T cells have been subject to studies within which it was hypothesized that they could induce remission in hemato-oncologic patients (Li et al., 2023). TCR $\gamma\delta$ has also been the subject of studies where bispecific antibodies were used to recruit TCR $\gamma\delta$ expressing T-cells, capable of targeting cells expressing tumor-antigens in AML, again demonstrating the promising possibilities of TCR $\gamma\delta$ in the context of hemato-oncological immune therapies (Ganesan et al., 2021).

1.5. Assessing leukemia-specific and blastolytic functionality of immune cells

The potential for cell lysis (of, e.g., leukemic blasts) can be measured using cytotoxicity assays such as fluorolysis-, chromium-51-release- and LDH- assays (Kienzle et al., 2002, Kumar et al., 2018, Grabrucker et al., 2010). Lysosomal-associated membrane glycoproteins (LAMPs), such as $CD107a$, remain on the cell surface after the release of the lytic granules and can be quantified using the degranulation assay (DEG) (Betts et al., 2003, Pepeldjyska et al., 2021, Schutti et al., 2024). Furthermore, the intracellular cytokine assay (INTCYT) can be used to detect and measure cytokines, such as tumor necrosis factor alpha (TNF α), which is known to induce cell apoptosis (Rath and Aggarwal, 1999, Letsch and Scheibenbogen, 2003, Pepeldjyska et al., 2021, Schutti et al., 2024).

1.6. Aims of the study

TCR $\gamma\delta$ expression on T-cells in peripheral WB from AML/MDS patients and healthy volunteers was analysed with a special focus on the role of Kit-pretreated WB to influence the TCR $\gamma\delta$ provision after mixed lymphocyte culture (MLC).

In detail, we investigated (the)

- APC/DC_(leu), their subtypes and the generation of APC/DC in patients' and healthy WB after Kit-treatment
- innate and adaptive immune cells, with a focus on TCR $\gamma\delta$ expressing T-cells, before and after MLC with Kit-pretreated vs. untreated (patients' and healthy) WB
- degranulation and intracellular cytokine production of TCR $\gamma\delta$ expressing T-cells in uncultivated (patients' and healthy) WB and after MLC with Kit-pretreated vs. untreated (patients' and healthy) WB
- blastolytic functionality of immune cells after MLC with Kit-pretreated vs. untreated (patients) WB
- correlations between TCR $\gamma\delta$ expressing T-cells, blastolytic activity and leukemia-specific activity in patients' samples
- correlations between TCR $\gamma\delta$ expressing T-cells in uncultivated patients' samples and response to chemotherapy/cytogenetic risk of patients

2. Materials and methods

2.1. Acquisition of samples

Samples were acquired from the university hospitals in Munich (LMU), Tuebingen, Oldenburg, and Augsburg, the Diakonieklinikum in Stuttgart, and the Rotkreuzklinikum in Munich. Peripheral blood samples were collected from healthy volunteers and patients with diagnosed myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Patients gave consent in written and oral form in accordance with Helsinki guidelines and the vote (number: 33905) of the Ethic Committee of LMU in Munich.

2.2. Details of collected samples

Samples were collected from 42 AML or MDS patients and 21 healthy individuals. At sample collection, patients were on average 63.1(29–98) years old, healthy volunteers were 30.7(20–56) years old. The male:female ratio was 1:1 for patients and 1:1.33 for healthy volunteers. Patients' peripheral blood (PB) contained on average %Bla/cells: 32 (10–94) (immunocytologically determined) blasts. The FAB classification system was applied to classify AML cases (Bennett et al., 1976), and the WHO classification system to classify MDS cases (Swerdlow et al., 2017). The ELN classification was used to assess the cytogenetic risk for AML patients (Döhner et al., 2017) and a multifactorial risk assessment according to the IPSS-R classification system (Greenberg et al., 1997, Garcia-Manero et al., 2020) was conducted for MDS patients. More detailed patient information can be found in Table 2.

2.3. Sample preparation

Density gradient centrifugation was used to isolate mononuclear cells (MNCs) from WB, pretreated according to standard procedures (Böyum, 1968, Amberger et al., 2019). An aliquot of cells was directly frozen, another aliquot of MNCs underwent a $CD3^+$ T-cell-enrichment via MACS-microbead-technology (Miltenyi Biotec, Bergisch Gladbach, Germany) and were frozen for subsequent experimental use (Willasch et al., 2010, Pepeldjyska et al., 2021, Amberger et al., 2019).

Table 2
Patients' and healthy individuals' characteristics.

diagn.	no.	age	sex	subtype	stage	ic bla	blast phenotype [CD]	risk class.	response	exp.
AML	1444	35	f	p/M1	dgn.	41	33, 65, 15, 34, 117	favourable	yes	DC; MLC; CTX;
AML	1540	83	f	p/M1	dgn.	32	13, 34, 33, 15, 117, 56	favourable	no	DC; MLC; CTX;
AML	1618	63	m	p/M1	dgn.	13	117, 33, 13, 11b, 15	favourable	no	CTX; D/I;
AML	1427	52	m	p/M2	dgn.	94	13, 33, 34, 117	favourable	no	DC; MLC; CTX;
AML	1541	82	f	p/M2	dgn.	15	15, 34, 117	interm.	no	DC; MLC; CTX;
AML	1442	73	f	p/M4	dgn.	15	33, 13, 34, 117, 15	interm.	yes	DC; MLC; CTX;
AML	1459	54	m	p/M4	dgn.	51	33, 64, 15, 4, 56, 14	favourable	yes	DC; MLC; CTX;
AML	1614	53	f	p/M4	dgn.	35	34, 117, 14, 33, 13	interm.	yes	CTX; D/I;
AML	1430	79	m	p/M5	dgn.	62	13, 33, 34, 117	favourable	nd	DC; MLC; CTX;
AML	1432	34	m	p/M5	dgn.	57	34, 13, 33, 64, 4	interm.	yes	DC; MLC; CTX;
AML	1466	47	f	p/M5	dgn.	11	33, 15, 13, 117, 34	adverse	yes	DC; MLC; CTX;
AML	1575	62	f	p/M5a	dgn.	75	14, 56, 64, 65, 4	interm.	yes	DC; MLC; CTX;
AML	1452	44	m	p/nd	dgn.	11	34, 117, 33, 13	interm.	no	DC; MLC; CTX;
AML	1568	29	m	p/nd	dgn.	69	34, 117, 33, 13, 19, 20, 65	interm.	no	DC; MLC; CTX;
AML	1570	36	f	p/nd	dgn.	11	34, 117, 65, 13, 33	favourable	no	DC; MLC; CTX;
AML	1608	61	f	p/nd	dgn.	23	34, 117, 13, 33, 56, 65	favourable	yes	CTX; D/I;
AML	1612	76	m	p/nd	dgn.	20	34, 65, 117, 133, 13	adverse	no	CTX; D/I;
AML	1617	81	f	p/nd	dgn.	51	13, 33, 64, 34, 117, 56,	interm.	yes	CTX; D/I;
AML	1492	52	f	s/M2	dgn.	38	117, 34, 13, 33, 7, 15	nd	no	DC; MLC; CTX;
AML	1542	58	f	s/M4	dgn.	52	13, 33, 34, 117, 15, 65, 64, 2, 56, 14	adverse	no	DC; MLC; CTX;
AML	1426	61	f	s/M5	dgn.	34	13, 33, 34, 64, 117, 14	adverse	yes	DC; MLC; CTX;
AML	1464	72	m	s/nd	dgn.	38	34, 117, 13	nd	nd	DC; MLC; CTX;
AML	1555	46	f	s/nd	dgn.	20	33, 14, 15, 11, 117, 13	favourable	nd	DC; MLC;
AML	1574	56	m	s/nd	dgn.	41	34, 117, 15, 19	nd	no	DC; MLC; CTX;
AML	1604	59	f	s/nd	dgn.	12	117, 34, 13, 33, 65, 7	interm.	nd	CTX; D/I;
AML	1609	71	m	s/nd	dgn.	46	117, 56, 65, 33, 13, 7	favourable	yes	CTX; D/I;
AML	1610	82	f	s/nd	dgn.	14	117, 33, 14, 56	nd	nd	CTX; D/I;
AML	1615	79	f	s/nd	dgn.	70	34, 117, 13	interm.	no	CTX; D/I;
AML	1616	69	f	s/nd	dgn.	14	34, 117, 33, 20, 23	interm.	no	CTX; D/I;
AML	1621	71	m	s/nd	dgn.	21	34, 117, 5, 13,	adverse	no	CTX; D/I;
AML	1571	61	m	p/M2	rel.	18	117, 33, 13, 7	nd	yes	DC; MLC; CTX;
AML	1424	37	f	p/M4	rel.	13	13, 14, 33, 117	nd	nd	DC; MLC; CTX;
AML	1548	87	m	p/M5a	rel.	12	33, 15, 117, 34, 56	nd	no	DC; MLC; CTX;
AML	1449	78	m	s/nd	rel.	32	65, 14, 15, 33, 56, 34	nd	nd	DC; MLC; CTX;
AML	1482	75	m	s/nd	rel.	12	117, 13, 64, 15, 117, 33	nd	nd	DC; MLC; CTX;
AML	1546	80	m	p/nd	pers.	22	33, 34, 13, 117, 14, 65	nd	no	DC; MLC;
AML	1470	67	m	p/nd	PR a. SCT	38	33, 117, 34, 56, 65	nd	no	DC; MLC;

(continued on next page)

Table 2 (continued)

diagn.	no.	age	sex	subtype	stage	ic bla	blast phenotype [CD]	risk class.	response	exp.
AML	1457	63	m	s/nd	rel. a. SCT	37	34, 117, 13, 65 , 15	nd	no	DC; MLC; CTX;
AML	1543	61	m	p/nd	rel. a. SCT.	38	13, 33, 117 , 56, 34	nd	no	DC; MLC; CTX;
MDS	1567	98	f	MDS	dgn.	14	34, 117, 15 , 65 , 56, 14	very high	nd	DC; MLC; CTX;
MDS	1573	61	m	MDS	dgn.	12	34 , 117 , 65, 13	high	no	DC; MLC; CTX;
MDS	1572	63	f	MDS-EB2	dgn.	10	34 , 117 , 65, 33, 13	very high	no	DC; MLC; CTX;
healthy	1417	34	f							DC; MLC;
healthy	1418	22	m							DC; MLC;
healthy	1420	26	f							DC; MLC;
healthy	1421	27	f							DC; MLC;
healthy	1422	20	f							DC; MLC;
healthy	1425	27	m							DC; MLC;
healthy	1428	56	f							DC; MLC;
healthy	1429	22	f							DC; MLC;
healthy	1431	22	m							DC; MLC;
healthy	1436	25	m							DC; MLC;
healthy	1448	27	f							DC; MLC;
healthy	1458	21	f							DC; MLC;
healthy	1544	22	m							DC; MLC;
healthy	1545	32	m							DC; MLC;
healthy	1547	46	f							DC; MLC;
healthy	1566	54	f							DC; MLC;
healthy	1576	55	m							DC; MLC;
healthy	1578	32	m							DC; MLC;
healthy	1611	26	f							D/I;
healthy	1613	24	f							D/I;
healthy	1619	25	m							D/I;

diagn. diagnosis; no. sample number; m male f female; subtypes: p primary AML; s secondary AML; AML (FAB class.); MDS (WHO class.); rel. a. SCT relapse after stem cell therapy; rel. relapse; dgn. first diagnosis; pers. persisting disease; PR partial remission; nd no data; ic bla immunocytologically determined blasts; bold numbers: blast markers used for DC characterization; risk class. risk classification cytogenetic (ELN AML) and multifactorial (IPSS-R MDS); response, response to chemotherapy; exp. experiments conducted; DC dendritic cell generation; MLC Mixed lymphocyte culture; D/I degranulation and intracellular cytokine assay; CTX cytotoxic fluoro-lysis assay;

2.4. Generation of APC/DC_(leu)

WB samples were mixed with a combination of response modifiers (Kit-M (GM-CSF (concentration (conc.): 800 U/ml, granulocyte macrophage colony stimulating factor, Sanofi-Aventis, Frankfurt, Germany) and PGE1 (conc.: 1 µg/ml, prostaglandin E1, Santa Cruz Biotechnology, Dallas, Texas, US)) and Kit-I (GM-CSF (conc.: 800 U/ml) and Picibanil (conc.: 10 µg/ml, Chugai Pharmaceutical Co., Kajiwar, Japan))), or without any Kits as control (the same amount of cells were added to the cultures compared), in accordance with our APC/DC-generating protocols (Amberger et al., 2019, Schmetzer et al., 2007, Boeck et al., 2017). Kits were added on the first day and again after 2–3 days of incubation. APC/DC-cultures were harvested after 6–8 days, quantified and utilized in subsequent experiments (Amberger et al., 2019, Boeck

et al., 2017). In order to simplify abbreviations, Kit-M treated WB is referred to as DC(M) (instead of APC/DC(M)), Kit-I-treated WB as DC(I) (instead of APC/DC(I)), and untreated WB (control) as DC(C) (instead of APC/DC(C)),

2.5. MLC- T-cell enriched mixed lymphocyte cultures

T-cells were thawed (as described previously) and cultured with DC-containing Kit-pretreated WB (containing approximately 250.000 cells), and 50 U/ml IL-2 (PeproTech, Berlin, Germany) to stimulate T-cell activation and maturation. After six to eight days of incubation time, the cultures were harvested, and the composition of immune reactive cells quantified by flowcytometry. In addition, intracellular cytokine production (INTCYT), and degranulation assays (DEG) were evaluated and

the cytotoxicity fluorolysis assay (CTX) was performed (Amberger et al., 2019, Boeck et al., 2017, Schutti et al., 2024)). In this study, MLC(UC) refers to cells before MLC, and after MLC with untreated WB they are referred to as MLC(CC), with Kit-M-pretreated WB as MLC(M), and with Kit-I-pretreated WB as MLC(I).

2.6. INTCYT- intracellular cytokine- and DEG- degranulation assay

For the DEG and INTCYT, uncultured WB or cells after MLC with and without Kit-pretreatment were used (Schutti et al., 2024). The intracellular cytokine production, in this study specifically TNF α , can be used to characterize immune cell functionality (Rodríguez-Caballero et al., 2004). According to manufacturers' instruction, the release of cytokines (TNF α) was inhibited by adding Brefeldin A solution (conc.: 5 μ g/ml, BioLegend, San Diego, California, US). Cells were stained using PE/Cy7-conjugated TNF α antibodies (BioLegend, San Diego, California, US) (Pepeldjyska et al., 2021). CD107a on the cell surface can be used as a measure of degranulation and therefore of immune cell functionality (Aktas et al., 2009). Monensin solution (conc: 2 μ mol/l, BioLegend, San Diego, California, US) was added according to manufacturers' instruction to inhibit endocytosis processes possibly weakening the fluorescence of CD107a antibodies on the cell surface over time. Cells were stained using FITC-conjugated CD107a antibodies (BioLegend, San Diego, California, US) (Pepeldjyska et al., 2021).

2.7. CTX- cytotoxicity fluorolysis assay

The blastolytic potential of effector cells (immunoreactive cells after T-cell enriched MLC with or without Kit-pretreated WB) was quantified using the CTX. Therefore, effector cells and target cells (patients' blast containing MNC, stained with blast markers) were incubated together (group 1) and separately for comparison (group 2). Effector and target cells were quantified after 0, 3, and 24 hours of co-culture. Cell viability was quantified via flow cytometry using 7-AAD Staining Solution (7AAD, BD Biosciences, San Jose, California, US) as a viability marker. The blast lysis was determined by comparing viable blast cells in group 1 to group 2, and lysis improvement defined by blast lysis after MLC using Kit-pretreated to untreated WB (Kienzle et al., 2002, Amberger et al., 2019, Schutti et al., 2024, Klauer et al., 2022, Unterfrauner et al., 2023).

2.8. Cell quantification via flow cytometry

Cell quantification was performed via FACSCalibur four channel flow cytometer. Cell staining was carried out using monoclonal antibodies labelled with FITC (fluorescein- isothiocyanate), PE (phycoerythrin), PE/Cy 7 (phycoerythrin/ cyanine 7) and APC (allophycocyanin).

These were: FITC-conjugated antibodies against IgG*, CD34*, CD65*, CD33*, CD117**, CD15*, CD56**, CD3**, CD71*, ipo38****, CD19*, CD107a**, CD4**, CD45RO*, CD14*; PE-conjugated antibodies against IgG*, TCR $\gamma\delta$ **, CD 117*, CD80*, CD83*, CD56*, CD206*, CD3*, CD4**, PE/Cy7-conjugated antibodies against IgG*, CD15**, CD117*, CD19*, CD34*, CD197**, CD56*, CD4*, TNF α ***, CD3*, CD14**; APC-conjugated antibodies against IgG*, CD206**, CD80**, CD209**, CD83**, CD34*, CD117*, CD14*, CD56*, CD69**, CD45RO**, CD4**, CD3*, CD19*. Antibodies were supplied by Beckman Coulter (*, Brea, California, US), BD Biosciences (**, San Jose, California, US), BioLegend (***, San Diego, California, US), Santa Cruz Biotechnology (****, Dallas, Texas, US). 7AAD** was used to detect viable cells.

For APC/DC(_{leu}) quantification, blast markers with high expression (e.g. CD34, CD117, CD65, CD56 or CD15) and APC/DC markers with low/no expression on blasts (e.g. CD80, CD83, CD206 or CD209) were individually chosen for each patient (Campana and Behm, 2000, Schmetzer et al., 2007).

FIX & PERM Cell Fixation and Cell Permeabilization Kit (ThermoFisher Scientific, Darmstadt, Germany) was used to detect intracellular

markers (IPO38, INTCYT). Isotype samples were added as controls (Kufner et al., 2005, Amberger et al., 2019, Schutti et al., 2024).

2.9. Data analysis

BD CellQuest Pro (Becton Dickinson, Heidelberg, Germany) was used to analyse the flowcytometric data. Excel 2010 (Microsoft, Redmond, Washington, USA) and SPSS Statistics 26 (IBM, Armonk, New York, USA) were utilized for statistical analysis. Data was presented including means, standard deviations, and statistical significances. Analyses of differences between groups were conducted with the paired-t-test and the Wilcoxon-Mann-Whitney-U-test. The Pearson-correlation and the Spearman-correlation were used for correlation analyses. Significances were defined by $p \leq 0.05$ as significant and $p \leq 0.005$ as highly significant.

3. Results

3.1. Prologue

We analysed immune cell profiles with a focus on TCR $\gamma\delta$ expression on T-cells before and after MLC, and further correlated immune cell profiles with blastolytic functionality, as well as clinical risk groups and outcomes of patients. Abbreviations for all subsequently mentioned cell subpopulations are given in Table 1.

3.2. Generation of APC/DC(_{leu}) and their subtypes using WB

3.2.1. Significantly higher frequencies of APC/DC(subtypes) generated with Kit vs. control

Frequencies of APC/DC(_{leu}) and their subtypes in patients' and healthy samples were (highly) significantly higher after DC(M) and DC(I) compared to DC(C) (e.g. %DC(_{leu})/cells; %DC_{mat}/cells) (Fig. 1). Moreover, we found significantly higher frequencies of mature DC subsets compared to control (Fig. 1)-thereby confirming data as shown before (Klauer et al., 2022, Schutti et al., 2024).

3.2.2. Blast/monocytes proliferation was not increased after Kit-treatment compared to control

In Kit-treated as well as untreated WB, we found no significant differences in frequencies of proliferating blasts (Bla_{prol}-CD71, Bla_{prol}-IPO38; Fig. 1.A1) in patients' WB and in frequencies of proliferating monocytes (Mon_{prol}-CD71; Fig. 1.B2), as already shown before (Plett et al., 2022).

In conclusion, Kit-treated WB (compared to the untreated control) led to higher frequencies of APC/DCs and DC-subtypes (DC_{leu}, DC_{mat}, DC_{leu-mat}) without induction of (APC/DC-independent) proliferation of blasts (patients) or monocytes (healthy).

3.2.3. Cells of the innate and adaptive immunity in uncultured WB

While we could find low frequencies of different T-cell subtypes and innate immune cells in healthy and AML WB samples, frequencies of NK/cells were significantly higher in healthy samples compared to patients' samples (%NK/cells) (Fig. 2). Furthermore, we found significantly higher frequencies of TCR $\gamma\delta$ expressing T-cells in healthy samples (%T_{TCR $\gamma\delta$ +/CD3⁺}: 7–8%) compared to patients' samples (%T_{TCR $\gamma\delta$ +/CD3⁺}: 5–6%).

After MLC, frequencies of TCR $\gamma\delta$ expressing T-cells in healthy and patients' samples were comparable (Fig. 3.A), as were the frequencies of innate immune cells (Fig. 2). We generally found more innate as well as proliferating, non-naïve and/or memory T-cells (e.g., T_{non-naïve}/CD3⁺ (and T_{nonnaïve}CD4⁺/T_{CD4}⁺ and T_{non-naïve}CD4⁺/T_{CD4}⁺) and T_{CD4}⁺/CD3⁺) after MLC compared to before (Fig. 2), which is also true for TCR $\gamma\delta$ expressing T-cells (Fig. 3.A).




Fig. 1. DC_(leu)-generation using leukemic (A) and healthy (B) WB with and without Kit-treatment; WB-samples were cultivated with and without (control) Kits for 7 days. DC(M), DC(I), DC(C) refer to Kit M, Kit I and control WB-cultures; Average frequencies \pm standard deviation and dot plots of DC-subtype values in (A) leukemic (AML/MDS) and (B) healthy samples within (1) all cells and (2) other DC_(leu) subpopulations; (n) number of cases; Significance is defined as $p \leq 0.05$ (significant/ *) and $p \leq 0.005$ (highly significant/ **), all other comparisons were not statistically significant; Cell subpopulations are given in Table 2.

3.3. Immune cell stimulation after MLC with Kit-treated (compared to untreated) WB

3.3.1. Significantly higher frequencies of T- and CIK-cells found after MLC with Kit-pretreated (vs. untreated) WB

We analysed the composition of immune cells after MLC with Kit-pretreated WB and compared the results with the control after MLC with untreated WB. In patients' samples, T_{non-naïve} and T_{cm} could be found in significantly higher frequencies after MLC(M) compared to control (MLC(CC)) (%T_{non-naïve}/CD3⁺: MLC(M) vs. MLC(CC): $p \leq 0.05$; and %T_{cm}/CD3⁺: MLC(M) vs. MLC(CC): $p \leq 0.05$). Frequencies of innate immune cells were comparable. (Fig. 2.A)

No differences were found in healthy samples comparing MLC(M) or MLC(I) vs. the control (Fig. 2.B)

3.3.2. Significantly higher frequencies of TCR $\gamma\delta$ expressing immune reactive cells found after MLC with Kit-M-pretreated (vs. untreated) WB

In patients' samples, we were able to find highly significantly higher frequencies of TCR $\gamma\delta$ expressing cells within T-cells after MLC(M) compared to MLC(CC) (%T_{TCR $\gamma\delta$ +}/CD3⁺: MLC(M): 24.58 ± 15.80 , $p \leq 0.005$; MLC(CC): 19.67 ± 14.82). No significant differences were found between MLC(I) and MLC(CC). Similar results could be found in healthy donors' samples. (Fig. 3.A)

We summarize that Kit-M-treatment of WB resulted in higher frequencies of TCR $\gamma\delta$ expressing T-cells compared to control. Furthermore, frequencies of TCR $\gamma\delta$ expressing T-cells were higher within healthy (compared to patients) before MLC.

3.3.3. Degranulation and intracellular cytokine production significantly increased within TCR $\gamma\delta$ expressing immune reactive cells after MLC with Kit-M-pretreated (vs. untreated) WB in patients' samples

We found higher frequencies of degranulating and intracellular cytokine producing TCR $\gamma\delta$ expressing T-cells after MLC compared to uncultivated WB in patients' samples.

Furthermore, we found highly significantly higher frequencies of degranulating (%T_{TCR $\gamma\delta$ +}CD107a⁺/T_{TCR $\gamma\delta$ +}: MLC(M): 59.43 ± 31.39 , $p \leq 0.005$; MLC(CC): 53.24 ± 29.09) and intracellular cytokine producing (%T_{TCR $\gamma\delta$ +}TNF α ⁺/T_{TCR $\gamma\delta$ +}: MLC(M): 50.07 ± 27.90 , $p \leq 0.005$; MLC(CC): 38.87 ± 27.67) TCR $\gamma\delta$ expressing T-cells after MLC(M) compared to MLC(CC) in patients' samples. Differences in Kit-pretreated and untreated healthy samples and differences between healthy and patients' samples were not significant. (Fig. 3.B)

We summarize that Kit-M-pretreatment (compared to control) led to higher frequencies of degranulating and TNF α producing TCR $\gamma\delta$ expressing T-cells in patients' samples.

3.3.4. Immune cells showed a superior blastolytic functionality after MLC with Kit-M-pretreated (vs. untreated) WB

The cytotoxicity fluorolysis assay was used to analyse the blastolytic potential (lysis) of effector cells after MLC(M), MLC(I) and MLC(CC). We co-cultivated target (blast containing MNC) and effector cells (T-cell enriched MLC after culture) for 24 hours and analysed viable blast frequencies after 3 hours and 24 hours of incubation time and selected the best achieved blastolytic effect after either 3 hours or 24 hours of incubation time.




Fig. 2. Immune cell composition before and after T-cell enriched MLC with (A) leukemic and (B) healthy WB with and without Kit-pretreatment as stimulator cells. Immune cells were cultivated with Kit-pretreated and control WB for 7 days and quantified before and after MLC. MLC(M), MLC(I) and MLC(CC) refer to Kit M, Kit I and control MLC cultures after incubation, MLC(UC) to control culture before incubation; Average frequencies \pm standard deviation and dot plots of immune cell subpopulations in (A) leukemic (AML/MDS) and (B) healthy samples; (n) number of cases; Significance is defined as $p \leq 0.05$ (significant/ *) and $p \leq 0.005$ (highly significant/ **), all other comparisons were not significant;; Cell subpopulations are given in Table 2.

After 3 (24) hours of incubation time, blast lysis could be achieved in 71.05 (76.32)% of cases after MLC(M) compared to 56.41 (64.10)% of cases after MLC(CC) and 45.45 (54.55)% of cases after MLC(I). Selecting the best blastolytic effect, blast lysis could be achieved in 94.74% of cases after MLC(M) compared to 79.49% of cases after MLC(CC) and 81.82% of cases after MLC(I). Significantly more cases with best achieved blast lysis were found after MLC(M) compared to MLC(CC) ($p \leq 0.05$). (Fig. 4.A). Frequencies of lysed blasts were comparable after Kit-pretreated and control MLC in cases with achieved lysis.

After 3 (24) hours of incubation time, improved lysis (MLC(M)/MLC(I) compared to MLC(CC)) could be achieved in 60.53 (63.16)% of cases after MLC(M) compared to 36.36 (45.45)% of cases after MLC(I). Selecting the best blastolytic effect, improved lysis (MLC(M)/MLC(I) compared to MLC(CC)) could be achieved in 86.84% of cases after MLC(M) compared to 72.73% of cases after MLC(I). Improved lysis (MLC(M)/MLC(I) compared to MLC(CC)) could be found in significantly more

cases after MLC(M) compared to MLC(I) after 3 hours ($p \leq 0.05$) (Fig. 4. B1). Lysis improvement was comparable after Kit-M-pretreated and Kit-I-pretreated MLC in cases with improved lysis (Fig. 4.B2).

In conclusion, we observed a superior blastolytic functionality of effector cells after Kit-M-pretreated MLC compared to the control and Kit-I-pretreated MLC.

3.4. Correlation analyses

3.4.1. Patients with remission (vs. blast persistence) after chemotherapy showed higher frequencies of TCR $\gamma\delta$ expressing T-cells in uncultivated cells

We analysed AML patients' samples at first diagnosis before MLC and compared frequencies of TCR $\gamma\delta$ expressing T-cells in patients with an achieved vs. a non-achieved remission after induction chemotherapy. Even though differences were not significant (due to low number of cases), we could find nearly significantly higher frequencies of TCR $\gamma\delta$




Fig. 3. Composition of (A) $TCR\gamma\delta$ expressing T-cells and (B) degranulating and intracellular cytokine producing of $TCR\gamma\delta$ expressing T-cells before and after T-cell enriched MLC with leukemic and healthy WB with and without Kit-pretreatment as stimulator cells. Immune cells were cultivated with Kit-pretreated and control WB for 7 days and quantified before and after MLC. DEG and INTCYT were quantified in uncultivated WB and after MLC. MLC(M), MLC(I) and MLC(CC) refer to Kit M, Kit I and control MLC of immune cells co-cultivated with DC culture, MLC(UC) to the control culture before cultivation, WB to whole blood; Average frequencies \pm standard deviation and dot plots of (A) $TCR\gamma\delta$ co-expressing T-cells and (B) degranulating and intracellular cytokine producing $TCR\gamma\delta$ co-expressing T-cells; (n) number of cases; Significance is defined as $p \leq 0.05$ (significant/ *) and $p \leq 0.005$ (highly significant/ **), all other comparisons were not statistically significant; Cell subpopulations are given in Table 2;.




Fig. 4. Blastolytic potential of immune cells after T-cell enriched MLC with leukemic WB with and without Kit-pretreatment as stimulator cells. Target and effector cells were co-cultivated for 24 hours. Figures show results after 3 hours, 24 hours and the best of achieved/improved lysis values after either 3 hours or 24 hours of incubation time. MLC(M), MLC(I) and MLC(CC) refer to Kit M, Kit I and control cultures; Percentage of cases (A) with (lysis) and without (no lysis) lysis and (B1) with (improved lysis) and without (no improved lysis) improvement of blast lysis compared to MLC(CC); Averages \pm standard deviation and dot plots of (B2) improvement of blast lysis compared to MLC(CC) within cases with improved blast lysis; (n) number of cases; Significance is defined as $p \leq 0.05$ (significant/ *), all other comparisons were not statistically significant; Cell subpopulations are given in Table 2.

expressing T-cells in patients with an achieved remission ($p < 0.1$) (Fig. 5. A).

3.4.2. Positive correlation of increased $TCR\gamma\delta$ expression on T-cells and blastolytic functionality

We correlated $TCR\gamma\delta$ expression on T-cells with blastolytic functionality as evaluated by a cytotoxicity assay. Increased frequencies of $TCR\gamma\delta$ expressing T-cells nearly significantly correlated with increased blast lysis after MLC(M) compared to MLC(CC) ($r = 0.411$; $p = 0.058$) (Fig. 5.B).

3.4.3. Positive correlation of $TCR\gamma\delta$ expression, blastolytic functionality and degranulation

We correlated frequencies of $TCR\gamma\delta$ expressing T-cells, of degranulating $TCR\gamma\delta$ expressing T-cells and blastolytic cytotoxicity. We found a non-significant positive correlation between frequencies of $TCR\gamma\delta$ expressing T-cells and frequencies of degranulating $TCR\gamma\delta$ expressing T-

cells after Kit-M-pretreated MLC ($r = 0.542$; $p = 0.085$) (Fig. 5.C1). However, we found a significant positive correlation of frequencies of degranulating $TCR\gamma\delta$ expressing T-cells with frequencies of lysed blasts after Kit-M-pretreated MLC ($r = 0.670$; $p = 0.024$) (Fig. 5.C2). Degranulating $TCR\gamma\delta$ expressing T-cells after Kit-M-pretreated MLC correlated non-significantly positively with lysis improvement after Kit-M-pretreated MLC compared to control ($r = 0.565$; $p = 0.070$) (Fig. 5.C4). Moreover, increased frequencies of degranulating $TCR\gamma\delta$ expressing T-cells correlated highly significantly positively with increased blast lysis after Kit-M-pretreated MLC compared to control ($r = 0.882$; $p < 0.001$) (Fig. 5.C3).

In conclusion, compared to control, higher frequencies of DC_{leu} and their subtypes were generated with Kit-treatment of WB, leading to improved stimulation and activation of immune reactive cells including $TCR\gamma\delta$ expressing T-cells. These $TCR\gamma\delta$ expressing T-cells showed higher levels of degranulation and intracellular cytokine production after Kit-pretreated MLC (vs. control). Kit-M-pretreatment also led to a superior




Fig. 5. Correlations of frequencies of TCR $\gamma\delta$ expressing T-cells within clinical/ functional subgroups or with blastolytic functionality. Immune cells were cultivated with Kit-pretreated and control WB for 7 days and quantified before and after MLC. MLC(M) and MLC(CC) refer to Kit M and control MLC of immune cells co-cultivated with DC culture, MLC(UC) to control culture before cultivation. Lysis (improvement/difference) refers to the best of value of MLC(M) (vs. MLC(CC)). Lysis improvement refers to a relative increase, difference refers to an absolute increase in blast lysis in MLC(M) compared to MLC(CC). Average frequencies \pm standard deviation and dot plots of TCR $\gamma\delta$ co-expressing T-cells in AML patients' WB (MLC(UC)) at initial diagnosis with (A) differences in response to chemotherapy; (B) correlations between differences in blast lysis and increase in frequencies of TCR $\gamma\delta$ expressing T-cells after MLC(M) (compared to MLC(CC)); (C) correlations between (frequencies after MLC(M)/increased frequencies after MLC(M) vs. control) of degranulating TCR $\gamma\delta$ expressing T-cells and frequencies of TCR $\gamma\delta$ expressing T-cells (C1), blast lysis (C2), the difference in blast lysis (C3), or lysis improvement (C4) after MLC(M) (vs. control (C3, C4)); (n) number of cases; Significance is defined as $p \leq 0.05$ (significant/ *) and $p \leq 0.005$ (highly significant/ **); Cell subpopulations are given in Table 2.

blastolytic cytotoxicity that correlated with higher frequencies of degranulating TCR $\gamma\delta$ expressing T-cells which also correlated positively with higher frequencies of TCR $\gamma\delta$ expressing T-cells. Additionally, the Kit-M-triggered promotion of frequencies of (degranulating) TCR $\gamma\delta$

expressing T-cells after MLC correlated with the increased blastolytic functionality. Finally, higher frequencies of TCR $\gamma\delta$ expressing T-cells in uncultivated AML patients' samples at first diagnosis tendentially pointed to a higher chance to achieve remission for patients after

induction chemotherapy.

4. Discussion

4.1. Immune therapies as a focus of hematological research

DC/DC_{leu} have shown high potential for immune therapies due to their special natural role facilitating immune response (Behrends et al., 2016; Amberger et al., 2019; Estey, 2020; Garcia-Manero et al., 2020). DC-generating methods can be used to derive DCs from myeloid blasts or monocytes (Schmetzer et al., 2007; Kremser et al., 2010), and have been shown to have various effects on the (leukemia specific) activation/composition of immune cells as well as their marker/antigen profiles (Klauer et al., 2022; Rackl et al., 2022; Vogt et al., 2014; Pepeldjyska et al., 2021). Further developments in immune therapeutic approaches, e.g. to induce DC/DC_{leu} in vivo, might help to improve therapy options and outcomes for patients with AML/MDS (Amberger and Schmetzer, 2020; Estey, 2020; Garcia-Manero et al., 2020; Klauer et al., 2022; Rackl et al., 2022; Röllig et al., 2019).

4.2. Immune cell stimulation mediated by Kit-treated WB

4.2.1. Generation of APCs/DCs and stimulation of immune cells

We could confirm that Kit-treatment (vs. control) of (healthy and patients) WB led to an increased generation of APCs/DCs and their subtypes (Amberger et al., 2019; Boeck et al., 2017; Hirn Lopez et al., 2019) (Fig. 1). We attribute this to the influence of GM-CSF and PGE1 (Kit-M) or GM-CSF and Picibanil (Kit I) on the intricate interplay of response modifiers (such as interleukins and chemokines) inherent in the microenvironment already contained in WB (Schwepcke et al., 2022; Amberger et al., 2019). Whereas frequencies of mature, leukemia-derived DC using Kit-treatment of WB (vs. control), were increased, no induction of monocytes or blasts proliferation was found, supporting preliminary data that Kit-treatment of WB does not induce the proliferation of blasts/monocytes (Plett et al., 2022; Amberger et al., 2019) (Fig. 1). These results are independent of patients' sex, age, mutation status cytogenetic risk or blast counts, and might therefore prove and qualify to stabilize patients' remissions, which remains to be proven clinically (Klauer et al., 2022; Klauer et al., 2024).

We could furthermore observe a (significant) stimulation of the adaptive and innate immunity after MLC with Kit-pretreated WB (vs. control): This includes significantly increased frequencies of non-naïve and central memory T-cells in patients' samples (Fig. 2). This might indicate that Kit-pretreated WB might activate immune cells and give rise to the immunological memory, as shown before (Amberger et al., 2019; Amberger and Schmetzer, 2020; Boeck et al., 2017; Klauer et al., 2022; Plett et al., 2022; Klauer et al., 2024). Furthermore, similar to Boeck et al., we found higher frequencies of innate immune cells in healthy (vs. patients) samples (Boeck et al., 2017) (Fig. 2), which might be due to various bacterial, mycotic or viral antigens presented by healthy DC, leading to the activation of healthy immunoreactive cells (Logan et al., 2020; Teague and Kline, 2013; Rabinovich et al., 2007). The observed broad immune cell activation after MLC (vs. before) might be caused by the effect of IL-2 added to cultures (Schorle et al., 1991) (Fig. 2, Fig. 3.A).

4.2.2. MLC with Kit-M-pretreated WB (vs. control) led to increased frequencies of TCR $\gamma\delta$ expressing T-cells, which were more prevalent in healthy (vs. patients) samples before cultivation

TCR $\gamma\delta$ has shown high potential in the context of potentially new and already known immune therapies (Hannani et al., 2012; Vantourout and Hayday, 2013; Ganesan et al., 2021). Significantly higher frequencies of TCR $\gamma\delta$ expressing T-cells were found in healthy (vs. patients) samples before cultivation (Fig. 3.A), which might be explained by the general immunosuppressive conditions in neoplastic diseases like AML as already shown (Logan et al., 2020; Rabinovich et al., 2007), which

might point towards healthy, TCR $\gamma\delta$ expressing T-cells having a functional, antileukemic role in healthy individuals.

We could also find higher frequencies of TCR $\gamma\delta$ expressing T-cells after MLC with Kit-M-pretreated (vs. control) healthy and patients' WB (Fig. 3.A; %T_{TCR $\gamma\delta$ +/CD3⁺}: MLC(M): 24.58±15.80, $p \leq 0.005$; MLC(CC): 19.67±14.82 in patients), pointing to a possible functional role of TCR $\gamma\delta$ expressing T-cells enabling Kit-M-mediated effector mechanisms.

Klauer et al. showed that Kit-I-treatment (vs. Kit-M-treatment) might lead to increased frequencies of DC, but possibly going along with a weaker induced functionality (Klauer et al., 2024). Similarly, we found higher frequencies of DC (in healthy samples) after DC(I) (vs. DC(M)) (Fig. 1).

4.2.3. MLC with Kit-M-pretreated patients' WB (vs. control) led to increased frequencies of degranulating/ intracellular cytokine producing TCR $\gamma\delta$ -expressing T-cells

Immune cell degranulation and the production of intracellular cytokines (e.g. TNF α) can be quantified via DEG and INTCYT assays and are valuable tools to describe (specific) immune cell activation (Klauer et al., 2022; Pepeldjyska et al., 2021), and can therefore link the activating effect of DCs after MLC with improved antileukemic effects, increased immune cell activation and ultimately, reduced blast counts (Klauer et al., 2022; Rackl et al., 2022; Pepeldjyska et al., 2021).

We found significantly higher frequencies of degranulating and intracellular cytokine producing TCR $\gamma\delta$ expressing T-cells after MLC with patients' Kit-M-pretreated (vs. control) WB (Fig. 3.B) □ Kit-M-pretreatment of WB was already shown to increase the degranulation and the cytokine production of immune cells compared to control, which might indicate an increased specifically induced antileukemic functionality of these Kit-M-induced TCR $\gamma\delta$ expressing T-cells (Pepeldjyska et al., 2021; Klauer et al., 2022). No differences of frequencies of degranulating and intracellular cytokine producing T-cells could be found within healthy samples and comparing healthy and patients' samples (Fig. 3.B), which might point to comparable activation levels of degranulating and intracellular cytokine producing TCR $\gamma\delta$ expressing T-cells after MLC with Kit-pretreated vs. control WB in healthy samples (but could also be explained by the low number of healthy samples).

4.2.4. MLC with Kit-M-pretreated WB (vs. control) led to increased blastolytic functionality of immune reactive cells

Comparing the blast cytotoxicity of immune cells after MLC, we found significantly more cases with an achieved blast lysis after MLC(M) compared to control, but not after MLC(I) (Fig. 4). We conclude that Kit-M-pretreatment (vs. control) improves the antileukemic activation and the blastolytic functionality of immune cells after MLC, confirming results presented before (Pepeldjyska et al., 2021; Klauer et al., 2022; Klauer et al., 2024). The achieved and improved blast lysis was superior after MLC(M) compared to MLC(I) with comparable frequencies of lysed blasts and lysis improvement after MLC with Kit-M- and Kit-I-pretreatment. We conclude that Kit-M-pretreatment might be superior compared to Kit-I-treatment to achieve and improve blast lysis (Fig. 4).

Some cases showed a superior blast lysis after 3 hours, while other cases showed a superior blast lysis after 24 hours (of target and effector cell incubation). This might be explained by different pathways of cell apoptosis (lysis) induction, including fast (granzyme/perforin) pathways and slow (Fas/FasL) pathways (Klauer et al., 2022; Lowin et al., 1994).

4.3. Connecting TCR $\gamma\delta$ expressing T-cells with the blastolytic functionality

4.3.1. Higher frequencies of TCR $\gamma\delta$ expressing T-cells might indicate effective (chemo)therapy

In uncultured samples from healthy donors (vs. patients) with a functional immune system not affected by tumor immunosuppression (Rabinovich et al., 2007; Teague and Kline, 2013), we found higher

frequencies of TCR $\gamma\delta$ expressing T-cells. Tendentially significantly higher frequencies of TCR $\gamma\delta$ expressing T-cells were seen in uncultured WB-samples of patients (AML, first diagnosis) that achieved (vs not achieved) remission after induction chemotherapy (Fig. 5.A). These findings might point to a functional (antileukemic) role of TCR $\gamma\delta$ expressing T-cells or at least a predictive marker to monitor the response to induction chemotherapy, adding further leads to the scientific discourse on the role of TCR in combating hematological malignancies (Goyal and Nardi, 2022, Minculescu et al., 2019, Saura-Esteller et al., 2022).

4.3.2. Kit-M-mediated increase in TCR $\gamma\delta$ expression linked to a higher blastolytic functionality

We found positive correlations between the Kit-M-mediated increased frequencies of degranulating TCR $\gamma\delta$ expressing T-cells and the Kit-M-mediated increased blast lysis (Fig. 5.B and 5.C3). This indicates that the increase in frequencies of TCR $\gamma\delta$ expressing degranulating T-cells, detected after Kit-M-pretreatment of WB directly correlated with improved blastolytic functionality (Klauer et al., 2022) and might therefore be one of the leukemia specific immunological effects and/or mechanisms after Kit-treatment of WB (Fig. 5. C1, C2, C4). Additionally to the cytotoxic effects mediated by activated cells of the adaptive and innate immune (after stimulation with Kit M pretreated leukemic blood as demonstrated before (e.g. Klauer et al., 2022), this could indicate that TCR $\gamma\delta$ T cells also play a role in the mediation of antileukemic reactivities in Kit M pretreated settings -in addition to other antitumor reactivities as shown before (Bensussan et al., 1989, Li et al., 2023) or could be relevant via modulatory effects of TCR $\gamma\delta$ expressing T-cells towards other, e.g. cytotoxic effects of innate or adaptive (e.g. CD8⁺) T-cells, an effect that has been described in the past (Nakamizo et al., 2015). No (tendentially) significant correlations were found after MLC(I), possibly due to an inferior effect of Kit-I-pretreatment on the blastolytic functionality of immune cells after MLC compared to Kit-M-pretreatment, which has been described in the past (Klauer et al., 2022, Klauer et al., 2024).

The potential of TCR $\gamma\delta$ for immune therapies has been discussed in the past (Duval et al., 1995, Hannani et al., 2012, Vantourout and Hayday, 2013, Goyal and Nardi, 2022, Saura-Esteller et al., 2022). Even though the induced/increased cytotoxicity could not be assigned to a single mediation by TCR $\gamma\delta$ T cells, we can add that leukemia specific TCR $\gamma\delta$ expressing T-cells are induced by Kit-M-pretreatment of patients' WB- correlating with increased blastolytic functionality (Fig. 5.B, 5.C3), which might be mediated by a DC/DC_{leu} triggered activation of TCR $\gamma\delta$ expressing T-cells (Fig. 3.A) and/ or consecutive immunomodulatory effects as shown in previous works (Hannani et al., 2012, Devilder et al., 2006), which might mean a synergistic effect between TCR $\gamma\delta$ T cells and activated cells of the adaptive (e.g.: CD4, CD8 or B cells) or innate immune system (e.g.; NK, CIK, iNKT cells). The role of these cells in (Kit M related) improved blast lysis was shown before (e.g. Klauer et al., 2022, Schutti, 2024, Böck 2017). These findings could indicate that these TCR $\gamma\delta$ expressing T-cells possess a cytotoxic potential towards myeloid blasts, which might contribute to develop and refine strategies addressing antitumor immunity (Bensussan et al., 1989, Saura-Esteller et al., 2022).

5. Conclusion

In conclusion, TCR $\gamma\delta$ -expressing T-cells could be found in (uncultured) healthy and patients' samples. DCs and their subtypes could be generated using Kit-M-treatment of WB, leading to the activation of immune cells after MLC – thereby increasing frequencies of degranulating and intracellular cytokine producing TCR $\gamma\delta$ expressing T-cells and resulting in an increased blastolytic functionality. Furthermore, we found a correlation of the Kit-M-mediated effects on the provision of TCR $\gamma\delta$ expressing T-cells and blast lysis, making TCR $\gamma\delta$ related strategies interesting for future immunotherapies. These data point to (DC-

induced) leukemia-specific TCR $\gamma\delta$ T-cells contributing to the improving antileukemic functionality.

Author contributions

E.R. provided great parts of experimental data and all flow cytometric and statistical data analyses. A.H., H.A.R., L.L., L.K.K., S.U., E.P., C.A., M.W., F.D.-G., C.P. and D.C.A. contributed DC, MLC, CTX, and DEG/INTCYT experiments, which were analysed by E.R., as well as whole blood samples and patients' reports. P.B., D.K., J.S., A.R., and C.S. contributed leukemic whole blood samples and patients' reports. The study was designed by H.M.S. The manuscript was drafted by E.R. and H.M.S., and edited by E.R., H.M.S, N.R. and J.S.

Statement of ethics

Collection of samples was conducted with patients' informed consents according to Helsinki guidelines and the vote of the Ethic Committee of LMU in Munich (vote number: 33905).

Funding

The project was supported by intramural funding of HS. Lin Li was funded by grants of China Scholarship Council (CSC) (File No.201808210307). Fatemeh Doraneh-Gard was funded by grants of the DAAD (ID 21520154) and scholarship 2016–2017 of the Ludwigs Maximilians University Munich). The funders did not influence study design, collection and analysis of data, decisions to publish, or preparation of the manuscript.

CRediT authorship contribution statement

Christoph Schmid: Data curation. **Corinna L Seidel:** Data curation. **Anne Hartz:** Data curation. **Nina Reiter:** Data curation. **Elias Rackl:** Writing – review & editing, Writing – original draft, Visualization, Validation, Investigation, Formal analysis, Data curation. **Julian Stein:** Writing – review & editing. **Helga Maria Schmetzer:** Writing – review & editing, Validation, Supervision, Software, Resources, Project administration, Methodology, Funding acquisition, Conceptualization. **Fatemeh Doraneh-Gard:** Data curation. **Doris Kraemer:** Data curation. **Selda Ugur:** Data curation. **Peter Bojko:** Data curation. **Lara Kristina Klauer:** Data curation. **Daniel Christoph Amberger:** Data curation. **Lin Li:** Data curation. **Caroline Plett:** Conceptualization. **Hazal Aslan Rejesky:** Data curation. **Melanie Weinmann:** Data curation. **Andreas Rank:** Data curation. **Carina Amend:** Data curation. **Jörg Schmohl:** Data curation. **Elena Pepeldjiyska:** Data curation.

Declaration of Competing Interest

H.M.S. is involved with Modiblast Pharma GmbH (Oberhaching, Germany), holder of the European Patent 15 801 987.7–1118 and the US Patent 15–517627 “Use of immunomodulatory effective compositions for the immunotherapeutic treatment of patients suffering from myeloid leukemias”.

Data Availability

Data will be made available on request.

Acknowledgement

The authors thank patients, medical staff, and physicians for contributing patients' samples and diagnostic reports. The results of this article are part of the doctoral thesis of Elias Rackl at Ludwig-Maximilians-University in Munich.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.molimm.2024.09.007](https://doi.org/10.1016/j.molimm.2024.09.007).

References

- Aktas, E., Kucuksez, U.C., Bilgic, S., Erten, G., Deniz, G., 2009. Relationship between CD107a expression and cytotoxic activity. *Cell Immunol.* 254, 149–154.
- Alcover, A., Alarcón, B., Di Bartolo, V., 2018. Cell biology of T cell receptor expression and regulation. *Annu Rev. Immunol.* 36, 103–125.
- Amberger, D.C., Dorane-Gard, F., Gunsilius, C., Weinmann, M., Möbius, S., Kugler, C., Rogers, N., Böck, C., Ködel, U., Werner, J.O., Krämer, D., Eiz-Vesper, B., Rank, A., Schmid, C., Schmetzer, H.M., 2019. PGE(1)-containing protocols generate mature (Leukemia-Derived) dendritic cells directly from leukemic whole blood. *Int J. Mol. Sci.* 20 (18), 4590.
- Amberger, D.C., Schmetzer, H.M., 2020. Dendritic cells of leukemic origin: specialized antigen-presenting cells as potential treatment tools for patients with myeloid leukemia. *Transfus. Med. Hemother.* 47, 432–443.
- Ansprenger, C., Amberger, D.C., Schmetzer, H.M., 2020. Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)-With a focus on Dendritic cells of leukemic origin (DCLeu). *Clin. Immunol.* 217, 108467.
- Azad, A.K., Rajaram, M.V., Schlesinger, L.S., 2014. Exploitation of the mannose mannose receptor (CD206) in infectious disease diagnostics and therapeutics. *J. Cytol. Mol. Biol.* 1.
- Behrends, J., Bischofberger, J., Deutzmann, R., Ehmke, H., Frings, S., 2016. *Duale Reihe Physiologie*. Thieme.
- Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R., Sultan, C., 1976. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. *Br. J. Haematol.* 33, 451–458.
- Bensussan, A., Lagabriele, J.F., Castaigne, S., Boisson, N., Miclea, J.M., Benbunan, M., Degos, L., 1989. Human CD3 gamma delta + activated lymphocytes exhibit killer activity in vitro against autologous leukemic cells. *Nouv. Rev. Fr. Hematol.* 31, 129–132.
- Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douek, D.C., Roederer, M., Koup, R.A., 2003. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. *J. Immunol. Methods* 281, 65–78.
- Beutler, B., 2004. Innate immunity: an overview. *Mol. Immunol.* 40, 845–859.
- Boeck, C.L., Amberger, D.C., Dorane-Gard, F., Sutanto, W., Guenther, T., Schmohl, J., Schuster, F., Salih, H., Babor, F., Borkhardt, A., Schmetzer, H., 2017. Significance of frequencies, compositions, and/or antileukemic activity of (DC-stimulated) invariant NKT, NK and CIK cells on the outcome of patients with AML, ALL and CLL. *J. Immunother.* 40, 224–248.
- Bonilla, F.A., Oettgen, H.C., 2010. Adaptive immunity. *J. Allergy Clin. Immunol.* 125, S33–S40.
- Böyum, A., 1968. Separation of leukocytes from blood and bone marrow. *Introduction. Scand. J. Clin. Lab Invest Suppl.* 97, 7.
- Campana, D., Behm, F.G., 2000. Immunophenotyping of leukemia. *J. Immunol. Methods* 243, 59–75.
- Costa, G.P., Mensurado, S., Silva-Santos, B., 2023. Therapeutic avenues for $\gamma\delta$ T cells in cancer. *J. Immunother. Cancer* 11.
- Davies, D.M., Pugliese, G., Parente Pereira, A.C., Whilding, L.M., Larcombe-Young, D., Maher, J., 2024. Engineering a Dual Specificity $\gamma\delta$ T-Cell Receptor for Cancer Immunotherapy. *Biology* 13.
- Devilder, M.C., Maillet, S., Bouyge-Moreau, I., Donnadiet, E., Bonneville, M., Scotet, E., 2006. Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. *J. Immunol.* 176, 1386–1393.
- Dinardo, C.D., Maiti, A., Rausch, C.R., Pemmaraju, N., Naqvi, K., Daver, N.G., Kadia, T.M., Borthakur, G., Ohanian, M., Alvarado, Y., 2020. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. *Lancet Haematol.* 7, e724–e736.
- Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F.R., Büchner, T., Dombret, H., Ebert, B.L., Fenaux, P., Larson, R.A., Levine, R.L., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M., Sierra, J., Tallman, M.S., Tien, H.F., Wei, A.H., Löwenberg, B., Bloomfield, C.D., 2017. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood* 129, 424–447.
- Dorane-Gard, F., Amberger, D.C., Amend, C., Weinmann, M., Schwepcke, C., Klauer, L., Schutti, O., Hosseini, H., Krämer, D., Rank, A., 2024. Anti-leukemic effects induced by dendritic cells of leukemic origin from leukemic blood samples are comparable under hypoxic vs. normoxic conditions. *Cancers* 16, 2383.
- Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., Schreiber, R.D., 2002. Cancer immunoeediting: from immunosurveillance to tumor escape. *Nat. Immunol.* 3, 991–998.
- Duval, M., Yotnda, P., Bensussan, A., Oudhiri, N., Guidal, C., Rohrlisch, P., Boumsell, L., Grandchamp, B., Vilmer, E., 1995. Potential antileukemic effect of gamma delta T cells in acute lymphoblastic leukemia. *Leukemia* 9, 863–868.
- Estey, E.H., 2020. Acute myeloid leukemia: 2021 update on risk-stratification and management. *Am. J. Hematol.*
- Franks, S.E., Wolfson, B., Hodge, J.W., 2020. Natural Born Killers: NK Cells in Cancer Therapy. *Cancers* 12.
- Ganesan, R., Chennupati, V., Ramachandran, B., Hansen, M.R., Singh, S., Grewal, I.S., 2021. Selective recruitment of $\gamma\delta$ T cells by a bispecific antibody for the treatment of acute myeloid leukemia. *Leukemia* 35, 2274–2284.
- Garcia-Manero, G., Chien, K., Montalban-Bravo, G., 2020. Myelodysplastic syndromes: 2021 update on diagnosis, risk-stratification and management. *Am. J. Hematol.* 95, 1399–1420.
- Goyal, A., Nardi, V., 2022. Gamma/delta ($\gamma\delta$) T cells: the role of the t-cell receptor in diagnosis and prognosis of hematologic malignancies. *Am. J. Derm.* 44, 237–248.
- Grabrucker, C., Liepert, A., Dreyig, J., Kremser, A., Kroell, T., Freudenreich, M., Schmid, C., Schweiger, C., Tischer, J., Kolb, H.J., Schmetzer, H., 2010. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells. *J. Immunother.* 33, 523–537.
- Greenberg, P., Cox, C., Lebeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohayshiki, K., Toyama, K., Aul, C., Mufti, G., Bennett, J., 1997. International scoring system for evaluating prognosis in myelodysplastic syndromes. *Blood* 89, 2079–2088.
- Hannani, D., Ma, Y., Yamazaki, T., Déchanet-Merville, J., Kroemer, G., Zitvogel, L., 2012. Harnessing $\gamma\delta$ T cells in anticancer immunotherapy. *Trends Immunol.* 33, 199–206.
- hayday, A.C., 2000. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. *Annu Rev. Immunol.* 18, 975–1026.
- Hirm Lopez, A., Deen, D., Fischer, Z., Rabe, A., Ansprenger, C., Stein, K., Vogt, V., Schick, J., Kroell, T., Kraemer, D., Kolb, H.J., Tischer, J., Schmid, C., Schmetzer, H., 2019. Role of interferon (IFN) α in "Cocktails" for the generation of (leukemia-derived) dendritic cells (DCLeu) from blasts in blood from patients (pts) with acute myeloid leukemia (AML) and the induction of antileukemic reactions. *J. Immunother.* 42, 143–161.
- Kienzie, N., Olver, S., Buttigieg, K., Kelso, A., 2002. The fluorolysis assay, a highly sensitive method for measuring the cytolytic activity of T cells at very low numbers. *J. Immunol. Methods* 267, 99–108.
- Klauer, L., Amberger, D., Ugur, S., Aslan, H., Rackl, E., Blasi, C., Dorane-Gard, F., Plett, C., Gunsilius, C., Weinmann, M., Fischer, Z., Özkaya, E., Atzler, M., Kugler, C., Pepeldjyska, E., Völker, A., Schutti, O., Deen, D., Rank, A., Schmid, C., Schmohl, J., & Schmetzer, H. 2024. Blastmodulatory Kit-M generating leukaemia-derived dendritic cells (DCLeu) significantly improves anti-leukaemic activity in vitro of patients AML-type and -stage. Medizinische Klinik und Poliklinik III, University Hospital of Munich, Munich, Germany.
- Klauer, L.K., Schutti, O., Ugur, S., Dorane-Gard, F., Amberger, D.C., Rogers, N., Weinmann, M., Kraemer, D., Rank, A., Schmid, C., Eiz-Vesper, B., Schmetzer, H., 2022. Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro. *Transfus. Med. Hemother.* 49, 44–61.
- Kremser, A., Dressig, J., Grabrucker, C., Liepert, A., Kroell, T., Scholl, N., Schmid, C., Tischer, J., Kufner, S., Salih, H., Kolb, H.J., Schmetzer, H., 2010. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. *J. Immunother.* 33, 185–199.
- Kufner, S., Zitzelsberger, H., Kroell, T., Pelka-Fleischer, R., Salem, A., De Valle, F., Schweiger, C., Nuessler, V., Schmid, C., Kolb, H.J., Schmetzer, H.M., 2005. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions. *Scand. J. Immunol.* 62, 86–98.
- Kumar, P., Nagarajan, A., Uchil, P.D., 2018. Analysis of cell viability by the lactate dehydrogenase assay. *Cold Spring Harb. Protoc.* 2018, 465–468.
- Letsch, A., Scheibenbogen, C., 2003. Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining. *Methods* 31, 143–149.
- Li, C., Zhou, F., Wang, J., Chang, Q., Du, M., Luo, W., Zhang, Y., Xu, J., Tang, L., Jiang, H., Liu, L., Kou, H., Lu, C., Liao, D., Wu, J., Wei, Q., Ke, S., Deng, J., Liu, C., Mei, H., Hu, Y., 2023. Novel CD19-specific $\gamma\delta$ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma. *J. Hematol. Oncol.* 16, 5.
- Logan, C., Koura, D., Taplitz, R., 2020. Updates in infection risk and management in acute leukemia. *Hematol. Am. Soc. Hematol. Educ. Program* 2020, 135–139.
- Lowin, B., Hahne, M., Mattmann, C., Tschopp, J., 1994. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. *Nature* 370, 650–652.
- Mensurado, S., Blanco-Domínguez, R., Silva-Santos, B., 2023. The emerging roles of $\gamma\delta$ T cells in cancer immunotherapy. *Nat. Rev. Clin. Oncol.* 20, 178–191.
- Minculescu, L., Marquart, H.V., Ryder, L.P., Andersen, N.S., Schjoedt, I., Friis, L.S., Kornblit, B.T., Petersen, S.L., Hastrup, E., Fischer-Nielsen, A., Reekie, J., Sengelov, H., 2019. Improved overall survival, relapse-free-survival, and less graft-vs.-host-disease in patients with high immune reconstitution of TCR gamma delta cells 2 months after allogeneic stem cell transplantation. *Front. Immunol.* 10.
- Morath, A., Schamel, W.W., 2020. $\alpha\beta$ and $\gamma\delta$ T cell receptors: Similar but different. *J. Leukoc. Biol.* 107, 1045–1055.
- Nakamizo, S., Egawa, G., Tomura, M., Sakai, S., Tsuchiya, S., Kitoh, A., Honda, T., Otsuka, A., Nakajima, S., Dainichi, T., Tanizaki, H., Mitsuyama, M., Sugimoto, Y., Kawai, K., Yoshikai, Y., Miyachi, Y., Kabashima, K., 2015. Dermal V γ 4(+) $\gamma\delta$ T cells possess a migratory potency to the draining lymph nodes and modulate CD8(+) T-cell activity through TNF- α production. *J. Invest Dermatol.* 135, 1007–1015.
- Parkin, J., Cohen, B., 2001. An overview of the immune system. *Lancet* 357, 1777–1789.
- Paurević, M., Srajer Gajdošić, M., Ribić, R., 2024. Mannose ligands for mannose receptor targeting. *Int J. Mol. Sci.* 25.
- Pepeldjyska, E., Li, L., Gao, J., Blasi, C., Özkaya, E., Schmohl, J., Schmid, C., Rank, A., Kraemer, D., & Schmetzer, H.M. 2021. Leukemia-specific activity (IFN γ and TNF α production and degranulation) of adaptive and innate immune cells in specific regulatory T cells as a parameter to display leukemia derived dendritic cell (DCLeu)

- mediated immune responses in AML [in press with Journal of Immunobiology]. In: DEPARTMENT OF MEDICINE III, U. H. O. M., MUNICH, GERMANY (ed.).
- Plett, C., Klauer, L.K., Amberger, D.C., Ugur, S., Rabe, A., Fischer, Z., Deen, D., Hirn-Lopez, A., Gunsilius, C., Werner, J.-O., I, E.A., 2022. Immunomodulatory Kits do not induce AML-blasts' proliferation *ex vivo*: IPO-38 is an appropriate and reliable marker to detect and quantify proliferating blasts. *Clin. Immunol.* 242, 109083.
- Rabinovich, G.A., Gabrilovich, D., Sotomayor, E.M., 2007. Immunosuppressive strategies that are mediated by tumor cells. *Annu. Rev. Immunol.* 25, 267–296.
- Rackl, E., Li, L., Klauer, L.K., Ugur, S., Pepeldjyska, E., Seidel, C.L., Gunsilius, C., Weinmann, M., Doraneh-Gard, F., Reiter, N., Plett, C., Amberger, D.C., Bojko, P., Kraemer, D., Schmohl, J., Rank, A., Schmid, C., Schmetzer, H.M., 2022. Dendritic cell-triggered immune activation goes along with provision of (Leukemia-Specific) integrin beta 7-expressing immune cells and improved antileukemic processes. *Int. J. Mol. Sci.* 24, 463.
- Rath, P.C., Aggarwal, B.B., 1999. TNF-induced signaling in apoptosis. *J. Clin. Immunol.* 19, 350–364.
- Rodríguez-Caballero, A., García-Montero, A.C., Bueno, C., Almeida, J., Varro, R., Chen, R., Pandiella, A., Orfao, A., 2004. A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation. *Lab Invest* 84, 1387–1398.
- Röllig, C., Beelen, D.W., Braess, J., Greil, R., Niederwieser, D., Passweg, J., Reinhardt, D. & Schlenk, R.F. 2019. *Leitlinie Akute Myeloische Leukämie*, *Onkopedia, Deutsche Gesellschaft für Hämatologie und Onkologie* [Online]. Onkopedia, Deutsche Gesellschaft für Hämatologie und Onkologie. Available: (<https://www.onkopedia.com/de/onkopedia/guidelines/akute-myeloische-leukaemie-aml/>) (@@guideline/html/index.html) [Accessed 17.11.2020 2020].
- Saura-Esteller, J., De Jong, M., King, L.A., Ensing, E., Winograd, B., De Gruijl, T.D., Parren, P.W.H.I., Van Der Vliet, H.J., 2022. Gamma delta T-cell based cancer immunotherapy: past-present-future. *Front. Immunol.* 13.
- Schick, J., Vogt, V., Zerwes, M., Kroell, T., Kraemer, D., Köhne, C.H., Hausmann, A., Buhmann, R., Tischer, J., Schmetzer, H., 2013. Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations. *J. Immunother.* 36, 223–237.
- Schmeel, L.C., Schmeel, F.C., Coch, C., Schmidt-Wolf, I.G., 2015. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). *J. Cancer Res Clin. Oncol.* 141, 839–849.
- Schmetzer, H., Amberger, D., Klauer, L., Rackl, E., Atzler, M., Ugur, S., Plett, C., Rabe, A., Kugler, C., Rank, A., 2022. P07. 02 Control leukemia by inducing anti-cancer immune reactivity *in vivo*?—Potential of a DC-triggered mechanism. *BMJ Spec. J. Schmetzer, H.M., Kremser, A., Loibl, J., Kroell, T., Kolb, H.J., 2007. Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo. Leukemia* 21, 1338–1341.
- Schorle, H., Holtschke, T., Hünig, T., Schimpl, A., Horak, I., 1991. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. *Nature* 352, 621–624.
- Schutti, O., Klauer, L., Baudrexler, T., Burkert, F., Schmohl, J., Hentrich, M., Bojko, P., Kraemer, D., Rank, A., Schmid, C., Schmetzer, H., 2024. Effective and successful quantification of leukemia-specific immune cells in AML patients' blood or culture, focusing on intracellular cytokine and degranulation assays. *Int. J. Mol. Sci.* 25.
- Schwepecke, C., Klauer, L.K., Deen, D., Amberger, D.C., Fischer, Z., Doraneh-Gard, F., Gunsilius, C., Hirn-Lopez, A., Kroell, T., Tischer, J., 2022. Generation of leukaemia-derived dendritic cells (Dcleu) to improve anti-leukaemic activity in AML: selection of the most efficient response modifier combinations. *Int. J. Mol. Sci.* 23, 8333.
- Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., 2017. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon.
- Teague, R.M., Kline, J., 2013. Immune evasion in acute myeloid leukemia: current concepts and future directions. *J. Immunother. Cancer* 1, 1.
- Thol, F., Döhner, H., Ganser, A., 2024. How I treat refractory and relapsed acute myeloid leukemia. *Blood* 143, 11–20.
- Unterfrauner, M., Rejeski, H.A., Hartz, A., Bohlscheid, S., Baudrexler, T., Feng, X., Rackl, E., Li, L., Rank, A., Filippini Velázquez, G., 2023. Granulocyte-macrophage-colony-stimulating-factor combined with prostaglandin E1 create dendritic cells of leukemic origin from AML patients' whole blood and whole bone marrow that mediate antileukemic processes after mixed lymphocyte culture. *Int. J. Mol. Sci.* 24, 17436.
- Vantourout, P., Hayday, A., 2013. Six-of-the-best: unique contributions of $\gamma\delta$ T cells to immunology. *Nat. Rev. Immunol.* 13, 88–100.
- Vogt, V., Schick, J., Ansprenger, C., Braeu, M., Kroell, T., Kraemer, D., Köhne, C.H., Hausmann, A., Buhmann, R., Tischer, J., Schmetzer, H., 2014. Profiles of activation, differentiation-markers, or β -integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells. *J. Immunother.* 37, 331–347.
- Willasch, A., Eing, S., Weber, G., Kuçi, S., Schneider, G., Soerensen, J., Jarisch, A., Rettinger, E., Koehl, U., Klingebiel, T., Kreyenberg, H., Bader, P., 2010. Enrichment of cell subpopulations applying automated MACS technique: purity, recovery and applicability for PCR-based chimerism analysis. *Bone Marrow Transpl.* 45, 181–189.
- Yu, J., Sun, H., Cao, W., Song, Y., Jiang, Z., 2022. Research progress on dendritic cell vaccines in cancer immunotherapy. *Exp. Hematol. Oncol.* 11, 3.